Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Chronic Weight Management: In June 2021, the FDA approved semaglutide (Wegovy) at a higher dose of 2.4 mg for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia
Tirzepatide Tirzepatide acts on both GIP and GLP-1 receptors and may be prescribed instead of semaglutide, depending on the providers assessment
Absence of testing documentation raises immediate concerns
and have not been demonstrated by the FDA to be safe or effective for their intended use
US$ 26.36
US$ 26.93
US$ 23.76
US$ 29.36
